Epaminurad

Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It is a urate-lowering agent that selectively inhibits the human uric acid transporter 1 (hURAT1), promoting urate excretion.^[1][2] As of 2024, epaminurad is undergoing Phase 3 clinical trials to evaluate its efficacy and safety compared to febuxostat in gout patients across multiple Asian countries.^[3][1]

Epaminurad

Clinical data
Other names	URC102/UR-1102
Identifiers
IUPAC name (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone
CAS Number	1198153-15-9
PubChem CID	44608229
ChemSpider	35143241
UNII	0YP1ME85GH
ChEMBL	ChEMBL4640580
Chemical and physical data
Formula	C14H10Br2N2O3
Molar mass	414.053 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1COC2=C(N1C(=O)C3=CC(=C(C(=C3)Br)O)Br)C=NC=C2
InChI InChI=InChI=1S/C14H10Br2N2O3/c15-9-5-8(6-10(16)13(9)19)14(20)18-3-4-21-12-1-2-17-7-11(12)18/h1-2,5-7,19H,3-4H2 Key:ZMVGQIIOXCGAFV-UHFFFAOYSA-N